Statements (106)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
gptkb:brand |
| gptkbp:application |
apply to affected area
|
| gptkbp:approves |
gptkb:2016
gptkb:2022 gptkb:FDA gptkb:European_Medicines_Agency |
| gptkbp:availability |
prescription only
available in multiple countries |
| gptkbp:class |
proteolytic enzyme
debriding agent |
| gptkbp:clinical_guidelines_update |
updated regularly
|
| gptkbp:clinical_trial |
ongoing
Phase III positive outcomes multiple sites published in medical journals completed and ongoing multiple international trials |
| gptkbp:clinical_use |
gptkb:Burning_Man
burn care debridement of burns integrated into burn care protocols |
| gptkbp:collaborations |
with various research institutions
|
| gptkbp:community_health |
required
|
| gptkbp:competitors |
other burn treatment products
other burn treatments |
| gptkbp:contraindication |
hypersensitivity to bromelain
|
| gptkbp:country_of_origin |
gptkb:Israel
|
| gptkbp:developed_by |
gptkb:Medi_Wound_Ltd.
|
| gptkbp:dosage_form |
gptkb:gel
|
| gptkbp:drug_interactions |
none significant
|
| gptkbp:duration |
up to 14 days
varies by patient |
| gptkbp:effective_date |
2016-01-20
|
| gptkbp:fdareview_process |
expedited review
|
| gptkbp:feedback |
generally positive
|
| gptkbp:financial_support |
available through Medi Wound
|
| gptkbp:formulation |
gptkb:chemical_compound
gptkb:gel |
| gptkbp:funding |
public and private sources
supported by grants |
| gptkbp:healthcare |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nexo Brid
|
| gptkbp:indication |
eschar removal in burn wounds
eschar removal |
| gptkbp:ingredients |
collagenase
bromelain |
| gptkbp:international_guidelines |
included in burn treatment guidelines
|
| gptkbp:invention |
patented
|
| gptkbp:is_effective_against |
effective in eschar removal
|
| gptkbp:manufacturer |
gptkb:Medi_Wound_Ltd.
|
| gptkbp:market |
ongoing
|
| gptkbp:market_authorization |
conditional
|
| gptkbp:market_launch |
gptkb:2016
|
| gptkbp:marketed_as |
gptkb:Medi_Wound_Ltd.
gptkb:United_States multiple countries Nexo Brid brand name |
| gptkbp:mechanism_of_action |
enzymatic debridement
debridement of necrotic tissue |
| gptkbp:packaging |
single-use vial
single-use container |
| gptkbp:patient_education |
provided by healthcare professionals
important for use |
| gptkbp:patient_population |
adults and children
|
| gptkbp:pharmacokinetics |
local action
proteolytic activity |
| gptkbp:pharmacovigilance |
monitored by EMA
|
| gptkbp:post_approval_studies |
required
|
| gptkbp:price |
varies by region
varies by provider |
| gptkbp:provides_guidance_on |
recommended for severe burns
|
| gptkbp:publication |
numerous studies published
|
| gptkbp:regulatory_compliance |
approved
marketed EMA approval monitored by FDA |
| gptkbp:research |
ongoing clinical trials
|
| gptkbp:research_and_development |
ongoing studies
|
| gptkbp:route_of_administration |
topical application
topical |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:safety_measures |
ongoing post-market surveillance
|
| gptkbp:sales |
expanding
|
| gptkbp:service_frequency |
as needed
once daily |
| gptkbp:side_effect |
rare
local irritation |
| gptkbp:storage |
room temperature
|
| gptkbp:supply_availability |
widely available
|
| gptkbp:supply_chain |
available in pharmacies
managed by Medi Wound |
| gptkbp:supply_disruptions |
rare
|
| gptkbp:trade |
gptkb:Nexo_Brid
|
| gptkbp:training |
provided to healthcare providers
|
| gptkbp:treatment |
monitored post-treatment
improved healing |
| gptkbp:type_of_care |
high
|
| gptkbp:type_of_insurance |
may be covered by insurance
|
| gptkbp:used_for |
debridement of burn wounds
treatment of burn wounds burn wound treatment |
| gptkbp:bfsParent |
gptkb:Medi_Wound_Ltd.
gptkb:Medi_Wound |
| gptkbp:bfsLayer |
6
|